Why Altimmune Is Rising In Pre-market?
(RTTNews) - Altimmune (ALT) announced the FDA has granted Breakthrough Therapy Designation for pemvidutide, a 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with metabolic dysfunction-associated steatohepatitis.
Jerry Durso, CEO of Altimmune, said: "With this breakthrough designation and alignment with the FDA on registrational Phase 3 trial parameters, we are laser-focused on strengthening the foundation of Altimmune to advance pemvidutide through late-stage development guided by our commitment to serve patients and create value for our stakeholders."
Shares of Altimmune are up 19.4% to $4.19 in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.